Topical bacteriocin therapy with epidermicin NI01 for dermatological infections (TOBRADERM)

Amprologix是一家开发新型抗生素的公司，以应对抗菌素耐药性（AMR）的全球威胁。当细菌对抗生素产生耐药性时，AMR就会发生，并导致治疗失败和“耐药性”感染的死亡率增加。这些感染在2019年造成120多万人死亡，迫切需要新的抗生素。如果我们不开发新的抗生素，我们现有的医疗系统可能会失败，癌症治疗和常规手术可能会导致致命的感染。在这个TOBRADERM项目中，Amprologix将测试一种新的抗生素化合物，epidermicin NI 01，用于治疗皮肤感染，每年影响数百万人在英国，是超过10%的抗生素处方的原因。皮肤感染可能是轻微的，但也可能导致严重和致命的结果，并且它们越来越复杂的AMR。我们将开发表皮霉素用于外部（局部应用），直接应用于感染区域。这增加了杀灭作用，但也有助于保存目前的抗生素，口服或注射，用于治疗严重的感染，如血液中的感染。表皮霉素NI 01来自一类新的抗生素化合物，细菌素（小蛋白质样分子）。虽然细菌素尚未用于治疗患者，但表皮霉素具有许多特性，这些特性增加了它成为成功药物的机会。这些特性包括最大限度地降低先前细菌素停止发展的任何风险的特性：它对全球主要病原体具有非常有效的活性（“超级细菌”），包括那些对当前抗生素有抗性的细菌和皮肤感染的主要原因;毒性极低，即使在最近的动物安全测试中也是如此;由于它杀死目标细菌的新颖方式，抗性不太可能发生;我们已经开发出一种成本极低的生产系统。Epidermicin也不会杀死所有种类的细菌，这意味着它将靶向主要病原体，使其他皮肤细菌不受伤害，保护“微生物组”。Epidermicin是一种非常有前途的新抗生素，在TOBRADERM项目中的成功将使Amprologix进入新药市场，帮助其成长为“局部治疗”的全球领导者。这将创造就业机会，为公司创造收入，并能够开发一种治疗皮肤感染的新药，每年可能使英国超过100万人受益。

Amprologix is a company developing novel antibiotics to meet the global threat of antimicrobial resistance (AMR). AMR happens when bacteria become resistant to antibiotics and results in treatment failure and increased death from 'drug resistant' infections. These infections killed over 1.2 million people in 2019 and new antibiotics are urgently needed. If we don't develop new antibiotics, our current medical system may fail and things like cancer therapy and routine surgery may result in a fatal infection.In this TOBRADERM project, Amprologix will test a new antibiotic compound, epidermicin NI01, for treating skin infections, which affect millions of people every year in the UK and are the cause of more than 10% of all antibiotic prescriptions. Skin infections can be minor but can also result in severe and fatal outcomes, and they are increasingly complicated by AMR. We will develop epidermicin to be used externally (topical application), being applied directly to infected areas. This increases the killing action but also helps preserve current antibiotics, taken orally or by injection, for use against serious infections, like those in the blood.Epidermicin NI01 is from a new class of antibiotic compound, the bacteriocins (small protein-like molecules). Whilst bacteriocins are not used to treat patients yet, epidermicin has many features that increase the chance of it being a successful drug. These features include properties that minimise any risks that have stopped development of previous bacteriocins: it has very potent activity against globally leading pathogens ('superbugs'), including those that are resistant to current antibiotics and the leading causes of skin infections; toxicity is extremely low, even in recent safety tests in animals; resistance is very unlikely to occur due to the novel way it kills target bacteria; and we have developed an extremely low-cost production system. Epidermicin will also not kill all kinds of bacteria meaning it will target the main pathogens, leaving other skin bacteria unharmed, protecting the 'microbiome'.Epidermicin is an extremely promising new antibiotic and success in the TOBRADERM project will allow Amprologix to access new drug markets, helping it grow into a global leader in 'topical therapeutics'. This will create jobs, generate income for the company and enable development of a new drug to treat skin infections, potentially benefitting over 1 million people a year in the UK.